Libman Richard, Kwiakowski Thomas, Lyden Patrick, Grotta James C, Tilley Barbara C, Fagen Susan C, Levine Steven R, Broderick Joseph P, Lin Yan, Lewandowski Christopher, Frankel Micheal R
Department of Neurology, Long Island Jewish Medical Center, New Hyde Park, New York, USA.
J Stroke Cerebrovasc Dis. 2005 Mar-Apr;14(2):50-4. doi: 10.1016/j.jstrokecerebrovasdis.2004.11.002.
Hemorrhagic transformation of ischemic stroke occurs relatively frequently. Many patients with hemorrhagic infarction on brain imaging do not show obvious signs of clinical deterioration, and such intracerebral hemorrhage is, therefore, designated asymptomatic. As a post hoc analysis, we explored whether such asymptomatic intracerebral hemorrhage may exert possible subtle adverse effects that might lead to a worse long-term outcome. Patients had an ischemic stroke and were enrolled in the National Institute of Neurological Disorders and Stroke tissue plasminogen activator (t-PA) stroke trial (n = 624). Computed tomography brain scan was performed 24 hours, 7 to 10 days, and 3 months after stroke, and at any time when clinical deterioration was observed. A neuroradiologist blinded to clinical information evaluated each scan for the presence of hemorrhage. Symptomatic intracerebral hemorrhage was defined as a computed tomographically documented hemorrhage that was temporally and causally related to deterioration of the patient's clinical condition in the judgment of the clinical investigator. Asymptomatic intracerebral hemorrhage was defined as computed tomographically documented hemorrhage that was not associated with deterioration in the patient's neurologic condition in the judgment of the clinical investigator. Three-month favorable outcome was assessed using the National Institutes of Health Stroke Scale, Barthel Index, and modified Rankin Scale. Wilcoxon and Fisher's exact tests were performed to determine whether asymptomatic intracerebral hemorrhage had an effect on outcome at 3 months. In all, 21 (3.4%) patients had asymptomatic intracerebral hemorrhage (13 in the t-PA group and 8 in the placebo group, P = .16). There was no statistical interaction between treatment and asymptomatic intracerebral hemorrhage on 3-month favorable outcome (P = .31). Initial analysis suggested that asymptomatic intracerebral hemorrhage decreased the odds of a favorable outcome. When controlling for computed tomographic lesion volume, however, a difference in the odds of a favorable outcome could no longer be detected for those with asymptomatic intracerebral hemorrhage compared with those without asymptomatic intracerebral hemorrhage. Patients enrolled in the National Institute of Neurological Disorders and Stroke t-PA Stroke Study had better long-term outcome regardless of whether asymptomatic intracerebral hemorrhage occurred. Asymptomatic intracerebral hemorrhage does not appear to influence long-term outcome after ischemic stroke.
缺血性卒中的出血性转化相对常见。许多脑成像显示有出血性梗死的患者并无明显的临床恶化迹象,因此这种脑出血被称为无症状性脑出血。作为一项事后分析,我们探讨了这种无症状性脑出血是否可能产生细微的不良影响,进而导致更差的长期预后。患者患有缺血性卒中,并被纳入美国国立神经疾病和中风研究所组织型纤溶酶原激活剂(t-PA)卒中试验(n = 624)。在卒中后24小时、7至10天、3个月以及观察到临床恶化的任何时间进行脑部计算机断层扫描。一位对临床信息不知情的神经放射科医生对每次扫描进行出血情况评估。有症状性脑出血的定义为,经计算机断层扫描记录的出血,临床研究者判断其在时间和因果关系上与患者临床状况恶化相关。无症状性脑出血的定义为,经计算机断层扫描记录的出血,临床研究者判断其与患者神经状况恶化无关。使用美国国立卫生研究院卒中量表、巴氏指数和改良Rankin量表评估3个月时的良好预后。进行Wilcoxon检验和Fisher精确检验,以确定无症状性脑出血是否对3个月时的预后有影响。共有21例(3.4%)患者发生无症状性脑出血(t-PA组13例,安慰剂组8例,P = 0.16)。在3个月时的良好预后方面,治疗与无症状性脑出血之间无统计学交互作用(P = 0.31)。初步分析表明,无症状性脑出血降低了良好预后的几率。然而,在控制计算机断层扫描病变体积后,与无无症状性脑出血的患者相比,有无症状性脑出血的患者在良好预后几率方面不再有差异。无论是否发生无症状性脑出血,纳入美国国立神经疾病和中风研究所t-PA卒中研究的患者长期预后均较好。无症状性脑出血似乎不会影响缺血性卒中后的长期预后。